Prostate Neuroendocrine Carcinoma
Associated Genetic Biomarkers
NCI Definition: A small cell or rarely a large cell neuroendocrine carcinoma that arises from the prostate gland. 
Prostate neuroendocrine carcinomas most frequently harbor alterations in RB1, TP53, TMPRSS2, ERG, and PTEN .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and TMPRSS2-ERG Fusion are the most common alterations in prostate neuroendocrine carcinoma .
There are 4 clinical trials for prostate neuroendocrine carcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain prostate neuroendocrine carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open).
Pembrolizumab, abiraterone, and cabozantinib are the most common interventions in prostate neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.